CCEL vs BDX

For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.

2% revenue growth year-over-year, versus 2. 0% for Cryo-Cell International, Inc. (CCEL). Becton, Dickinson and Company (BDX) offers the better valuation at 24. 8x trailing P/E (11. 6x forward), making it the more compelling value choice. Analysts rate Becton, Dickinson and Company (BDX) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 24.

8x versus Cryo-Cell International, Inc. at 70. 6x.

Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +10.

4%, compared to -40. 2% for Cryo-Cell International, Inc. (CCEL). Over 10 years, the gap is even starker: BDX returned +72. 9% versus CCEL's +56. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cryo-Cell International, Inc.

(CCEL) is the lower-risk stock at 0. 35β versus Becton, Dickinson and Company's 0. 66β — meaning BDX is approximately 87% more volatile than CCEL relative to the S&P 500.

By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.

2% versus 2. 0% for Cryo-Cell International, Inc. (CCEL). On earnings-per-share growth, the picture is similar: Cryo-Cell International, Inc. grew EPS 104. 4% year-over-year, compared to -0. 5% for Becton, Dickinson and Company. Over a 3-year CAGR, BDX leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Becton, Dickinson and Company (BDX) is the more profitable company, earning 7.

7% net margin versus 1. 3% for Cryo-Cell International, Inc. — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDX leads at 11. 8% versus 10. 9% for CCEL. At the gross margin level — before operating expenses — CCEL leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

All stocks in this comparison pay dividends.

Cryo-Cell International, Inc. (CCEL) offers the highest yield at 7. 0%, versus 2. 9% for Becton, Dickinson and Company (BDX).

For long-horizon retirement investors, Cryo-Cell International, Inc.

(CCEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), 7. 0% yield). Both have compounded well over 10 years (CCEL: +56. 3%, BDX: +72. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CCEL is a small-cap income-oriented stock; BDX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.